Efficacy of baricitinib combined with ruxolitinib cream in the treatment of six patients with progressive nonsegmental vitiligo: a clinical observation
- VernacularTitle:巴瑞替尼联合芦可替尼乳膏治疗6例进展期非节段型白癜风患者的疗效观察
- Author:
Tingting ZHU
1
;
Weiran LI
;
Zhaobing PAN
;
Hao LIU
;
Xianfa TANG
;
Caihong ZHU
;
Hequn HUANG
;
Dawei DUAN
;
Ruochen ZHANG
;
Xiaojian CHEN
;
Yang WANG
;
Qian XUE
;
Jurui ZHANG
;
Lijing YANG
;
Xuejun ZHANG
;
He HUANG
;
Bo ZHANG
Author Information
- Publication Type:Journal Article
- Keywords: Vitiligo; Janus kinase inhibitors; Baricitinib; Ruxolitinib; Treatment outcome; Efficacy; Safety
- From: Chinese Journal of Dermatology 2025;58(9):856-859
- CountryChina
- Language:Chinese
- Abstract: Objective:To evaluate the efficacy and safety of baricitinib combined with ruxolitinib cream in the treatment of progressive nonsegmental vitiligo.Methods:Clinical data were retrospectively collected from patients with progressive nonsegmental vitiligo in Boao Super Hospital. All the patients were treated with oral baricitinib daily (2 mg/day for patients weighing ≤ 50 kg; 4 mg/day for those > 50 kg) in combination with topical application of ruxolitinib cream twice daily for 24 consecutive weeks. Disease severity was assessed using the facial vitiligo area scoring index (F-VASI) and total body VASI (T-VASI) at baseline, week 12, and week 24. Adverse reactions were monitored throughout the treatment course.Results:Six patients with progressive nonsegmental vitiligo were collected, including 3 males and 3 females, aged 26 - 42 years, with the disease duration ranging from 0.5 to 25 years. At week 12, 3 patients achieved a 50% ~ < 75% improvement in facial vitiligo lesions (F-VASI 50), 1 patient achieved F-VASI 75 (75% ~ < 90% improvement), and 1 patient achieved T-VASI 50; at week 24, 4 patients achieved F-VASI 50, 1 patient achieved F-VASI 75, 1 patient achieved F-VASI 90 (≥ 90% improvement), and 3 patients achieved T-VASI 50. During the treatment, upper respiratory infection occurred in 1 patient, acne in 1 patient, pruritus in 2 patients, elevation of total cholesterol levels in 2 patients, and increase of high-density lipoprotein levels in 2 patients. No severe adverse events were observed during the treatment.Conclusion:The combination therapy with baricitinib and ruxolitinib cream may have potential efficacy and safety in the treatment of progressive nonsegmental vitiligo.
